Issue 53, 2019

Oriented attachment of VNAR proteins, via site-selective modification, on PLGA–PEG nanoparticles enhances nanoconjugate performance

Abstract

Herein we report the construction of a nanoparticle-based drug delivery system which targets a key regulator in tumour angiogenesis. We exploit a Variable New Antigen Receptor (VNAR) domain, conjugated using site-specific chemistry, to direct poly lactic acid-co-glycolic acid–polyethylene glycol (PLGA–PEG) nanoparticles to delta like canonical Notch ligand 4 (DLL4). The importance of site-specific chemistry is demonstrated.

Graphical abstract: Oriented attachment of VNAR proteins, via site-selective modification, on PLGA–PEG nanoparticles enhances nanoconjugate performance

Supplementary files

Article information

Article type
Communication
Submitted
05 Apr 2019
Accepted
29 May 2019
First published
29 May 2019
This article is Open Access
Creative Commons BY license

Chem. Commun., 2019,55, 7671-7674

Oriented attachment of VNAR proteins, via site-selective modification, on PLGA–PEG nanoparticles enhances nanoconjugate performance

J. C. F. Nogueira, M. K. Greene, D. A. Richards, A. O. Furby, J. Steven, A. Porter, C. Barelle, C. J. Scott and V. Chudasama, Chem. Commun., 2019, 55, 7671 DOI: 10.1039/C9CC02655J

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements